CN114632195B - 一种抗凝促心肌组织修复的可降解封堵器及其制备方法 - Google Patents
一种抗凝促心肌组织修复的可降解封堵器及其制备方法 Download PDFInfo
- Publication number
- CN114632195B CN114632195B CN202210458430.2A CN202210458430A CN114632195B CN 114632195 B CN114632195 B CN 114632195B CN 202210458430 A CN202210458430 A CN 202210458430A CN 114632195 B CN114632195 B CN 114632195B
- Authority
- CN
- China
- Prior art keywords
- degradable
- occluder
- solution
- albumin
- tissue repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002107 myocardial effect Effects 0.000 title claims abstract description 41
- 230000017423 tissue regeneration Effects 0.000 title claims abstract description 35
- 230000010100 anticoagulation Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 102000009027 Albumins Human genes 0.000 claims abstract description 37
- 108010088751 Albumins Proteins 0.000 claims abstract description 37
- 102000008186 Collagen Human genes 0.000 claims abstract description 29
- 108010035532 Collagen Proteins 0.000 claims abstract description 29
- 229920001436 collagen Polymers 0.000 claims abstract description 29
- 238000000576 coating method Methods 0.000 claims abstract description 27
- 239000011248 coating agent Substances 0.000 claims abstract description 26
- 230000021164 cell adhesion Effects 0.000 claims abstract description 5
- 238000000855 fermentation Methods 0.000 claims abstract description 5
- 230000004151 fermentation Effects 0.000 claims abstract description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000010353 genetic engineering Methods 0.000 claims abstract description 4
- 229960002591 hydroxyproline Drugs 0.000 claims abstract description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000008367 deionised water Substances 0.000 claims description 24
- 229910021641 deionized water Inorganic materials 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000003146 anticoagulant agent Substances 0.000 claims description 20
- 238000005406 washing Methods 0.000 claims description 19
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 10
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 3
- 208000008883 Patent Foramen Ovale Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 3
- 210000005248 left atrial appendage Anatomy 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- -1 polyphenol compounds Chemical class 0.000 claims description 2
- 210000003157 atrial septum Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000000596 ventricular septum Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 29
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000037452 priming Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 2
- 239000008204 material by function Substances 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 51
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- 230000000702 anti-platelet effect Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 230000028709 inflammatory response Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 238000012545 processing Methods 0.000 description 9
- 239000000622 polydioxanone Substances 0.000 description 8
- 102000001187 Collagen Type III Human genes 0.000 description 6
- 108010069502 Collagen Type III Proteins 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 208000002330 Congenital Heart Defects Diseases 0.000 description 4
- 208000028831 congenital heart disease Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000003278 patent ductus arteriosus Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
- A61L33/122—Collagen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
Abstract
本发明公开了一种抗凝促心肌组织修复的可降解封堵器及其制备方法,涉及生物医学工程功能材料技术领域,所述可降解封堵器的表面覆有多层经活化处理液处理的白蛋白以及重组人源化胶原蛋白层,且以白蛋白为打底涂层,表面的白蛋白以及重组人源化胶原蛋白层参与交联反应。本发明经活化处理液及高温制备的白蛋白打底涂层,具有与基底可降解封堵器材料牢固的界面结合力,通过简易的层状梯度吸附组装,可有效地调节涂层中白蛋白及重组人源化胶原蛋白含量,所用重组人源化胶原蛋白,筛选规避了羟脯氨酸(O)且正负电荷相对集中的含有GER、GEK的细胞粘附性区段,为通过基因工程和发酵工程制备的胶原蛋白,是一种兼具抗凝血性能和促心肌组织修复性能的物质。
Description
技术领域
本发明涉及生物医学工程功能材料技术领域,具体涉及一种抗凝促心肌组织修复的可降解封堵器及其制备方法。
背景技术
先天性心脏病指在胚胎发育时期由于心脏及大血管的形成障碍或发育异常而引起的解剖结构异常,或出生后应自动关闭的通道未能闭合(在胎儿属正常)的情形。先天性心脏病如果未经有效治疗或干预,极易诱发心源性脑卒中。先天性心脏病发病率不容小视,我国每年新增先天性心脏病患者15~20万,其主要包括房间隔缺损、室间隔缺损、卵圆孔未必、动脉导管未闭等。作为心率失常最常见的疾病类型之一,房颤的发生也会也与心脏左心耳这一结构的存在也有密切的关联因素。伴随心脏结构封堵器的问世,为降低因这些因脏内器官关闭功能不全带来的潜在脑卒中风险提供了较为有效的干预手段。
然而,现有的心脏封堵器主要由超弹性镍钛合金丝编织而成,其本身不降解,而目前已上市的可降解封堵器,因未经抗凝或促组织修复的改性,性能尚有改善空间。现有封堵器植入后可能面临如下问题:1)永久不可降解的本体材料会引起机体组织的持续性炎症反应刺激,造成术后封堵包膜组织的异常增生,可能造成心脏功能不良修复;2)现有封堵器植入早期需持续口服抗凝药,这对于华法林禁忌类患者则不适用;3)可降解材料被机体吸收过程中,无法有效调节原有心肌组织的再生替代修复。近年来,以PDO及PLA为代表的可降解心脏封堵器逐渐问世,为该领域的介入治疗打开了新的窗口,而基于此,设计开发具有抗凝促心肌组织修复功能的可降解封堵器,对于扩大适应症及治疗效果,具有十分重要的临床意义。
发明内容
针对现有心脏封堵器材料植入后面临的凝血、促心肌组织修复性能不良等临床现状,本发明提供了一种抗凝促心肌组织修复功能的可降解封堵器及其制备方法。其主要涉及到可降解封堵器材料表面涂层的制备。涂层包括活化白蛋白的打底涂层,该涂层具有与基底材料的强界面结合力。抗凝及促心肌组织修复功能主要由涂层后续层状组装引入的白蛋白及重组人源化胶原蛋白提供,其中白蛋白是一种有效降低机体免疫应答、凝血应答及炎症反应的物质,重组人源化胶原蛋白免疫原性极低,可以发挥协同抗凝和促心肌组织修复的功能。通过后续的交联剂弱交联处理,则可以显著提升组装物的稳定性和耐久性。通过这类涂层的修饰,有望在可降解封堵器植入后,增强早期的抗凝和促心肌组织修复效果,更好的保障封堵器的服役性能。
本发明采用的技术方案如下:
一种抗凝促心肌组织修复的可降解封堵器,所述可降解封堵器的表面覆有多层经活化处理液处理的白蛋白以及重组人源化胶原蛋白层,且以白蛋白为打底涂层,表面的白蛋白以及重组人源化胶原蛋白层参与交联反应。
更优地,所述可降解封堵器的材料采用聚乳酸、聚对二甲基羟己酮、聚对二氧环己酮、聚乳酸羟基乙酸共聚物、聚己内酯中的一种或多种。
更优地,所述白蛋白为牛血清白蛋白、人血清白蛋白、羊血清白蛋白以及他们的重组白蛋白中的一种或多种。
更优地,所述重组人源化胶原蛋白为不含有血小板结核性羟脯氨酸(O)且包含正负电荷相对集中的GER、GEK细胞粘附性序列的重组人源化胶原蛋白多肽片段,经基因工程和发酵工程制备的重组人源化胶原蛋白,其蛋白分型包括重组人源化一型到二十八型,分子量范围为5千~100万。
所述的抗凝促心肌组织修复的可降解封堵器的制备方法,包括如下步骤:
(1)配置白蛋白溶液,浓度为0.01wt%-2wt%;
(2)将可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加活化处理液,添加比例为0.05wt%-2wt%,在50-80℃条件下,反应10min-6h,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化胶原蛋白溶液中,pH 5.5,浓度0.01wt%-2wt%,常温下处理10-60min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在白蛋白溶液中pH 5.5,浓度0.01wt%-2wt%,常温下处理10-60min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化胶原蛋白溶液中,pH 5.5,浓度0.01wt%-2wt%,常温下处理10-60min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),可循环处理1到10次,获得可降解封堵器F;
(7)可降解封堵器F置于交联剂溶液中,交联剂浓度为0.01wt%-1wt%,常温处理10min-60min,即获得具有抗凝促心肌组织修复的可降解封堵器G。
进一步地,步骤(2)中,所述活化处理液为还原性谷胱甘肽、过硫酸盐、三(2-羧乙基)膦、双氧水及其他能产生活性自由基的化合物中的一种或多种。
进一步地,步骤(7)所述交联剂为戊二醛、京尼平、碳二亚胺盐酸盐类、多酚类化合物等中的一种或多种。
所述的抗凝促心肌组织修复的可降解封堵器在左心耳封堵器、房间隔、室间隔封堵器、卵圆孔未闭封堵器上的应用。
综上所述,相比于现有技术,本发明具有如下优点及益效果:
1、本发明经活化处理液及高温制备的白蛋白打底涂层,具有与基底可降解封堵器材料牢固的界面结合力,且通过简易的层状梯度吸附组装,可有效的调节涂层中白蛋白及重组人源化胶原蛋白含量。
2、本发明中所用的重组人源化胶原蛋白,为不含有血小板结核性羟脯氨酸(O),但包含正负电荷相对集中的GER、GEK细胞粘附性序列的重组人源化胶原蛋白多肽片段,经基因工程和发酵工程制备的重组胶原蛋白,其蛋白分型包括重组人源化一型到二十八型,分子量范围5千到100万不等。以重组人源化三型胶原蛋白为例,它是基于483GERGAPGFRGPAGPNGIPGEKGPAGERGAP512重复序列的,分子量约45万的重组胶原蛋白,是一种兼具抗凝血性能和促组织修复性能的物质;其他重组人源化胶原蛋白按上述策略筛选,经基因和发酵工程也可以合成具有低免疫原性,可促心肌组织修复的重组人源化胶原蛋白。
3、本发明通过简便的投料浓度、反应温度、时间等调节,可以制备不同厚度及组装物含量的涂层,可针对不同封堵器材料的骨架、阻流膜等进行有效的涂敷。
附图说明
图1为实施例1中可降解封堵器所用的聚对二氧环己酮材料表面经涂层处理后的血小板黏附结果对比图;
图2为实施例1中可降解封堵器所用的聚对二氧环己酮材料表面经涂层处理后的血小板黏附结果对比图;
图3为实施例1中可降解封堵器所用的聚对二氧环己酮材料表面经涂层处理后的促心肌细胞黏附结果对比图。
具体实施方式
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。
实施例1
一种具有抗凝促心肌组织修复功能的可降解封堵器及其制备方法,包含以下步骤:
(1)配置人血清白蛋白溶液(0.05wt%);
(2)将采用聚对二氧环己酮材料制备的可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加还原性谷胱甘肽(0.1wt%),在60℃条件下,反应20min,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化三型胶原蛋白溶液中(pH 5.5,0.05wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在人血清白蛋白溶液中(pH 5.5,0.05wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化三型胶原蛋白溶液中(pH 5.5,0.05wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),循环处理2次,获得可降解封堵器F;
(7)可降解封堵器F置于戊二醛溶液中(0.05wt%),常温处理20min,即获得终端产品,即具有抗凝促心肌组织修复的可降解封堵器G。
如图1~图3所示,为本实施例所制备的可降解封堵器G与未经处理的可降解封堵器A关于抗血小板黏附与聚集能力、引发的炎症应答水平以及对心肌细胞生长的亲和能力的实验对比图,由图1不难得出结论:表明涂层改性可以有效提升可降解封堵器的抗血小板黏附与聚集能力;由图2不难得出结论:涂层改性可以有效降低可降解封堵器材料引发的炎症应答水平;由图3不难得出结论:表明涂层改性可以有效促进可降解封堵器材料表面对心肌细胞生长的亲和能力。
实施例2
一种具有抗凝促心肌组织修复功能的可降解封堵器及其制备方法,包含以下步骤:
(1)配置牛血清白蛋白溶液(1wt%);
(2)将采用聚对二氧环己酮材料制备的可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加过硫酸铵(0.1wt%),在50℃条件下,反应30min,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化一型胶原蛋白溶液中(pH 5.5,0.1wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在牛血清白蛋白溶液中(pH 5.5,0.05wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化一型胶原蛋白溶液中(pH 5.5,0.1wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),循环处理3次,获得可降解封堵器F;
(7)可降解封堵器F置于碳二亚胺(EDC)溶液中(0.2wt%),常温处理30min,即获得终端产品,即具有抗凝促心肌组织修复的可降解封堵器G。
对本实施例所制备的可降解封堵器G与未经处理的可降解封堵器A进行关于抗血小板黏附与聚集能力、引发的炎症应答水平以及对心肌细胞生长的亲和能力的实验,结果同实施例1一样(因附图与实施例1较为接近,故而本实施例省略附图):涂层改性可以有效提升可降解封堵器的抗血小板黏附与聚集能力,可以有效降低可降解封堵器材料引发的炎症应答水平,可以有效促进可降解封堵器材料表面对心肌细胞生长的亲和能力。
实施例3
一种具有抗凝促心肌组织修复功能的可降解封堵器及其制备方法,包含以下步骤:
(1)配置重组人血清白蛋白溶液(0.05wt%);
(2)将采用聚对二甲基羟己酮材料制备的可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加还原性谷胱甘肽(0.1wt%),在60℃条件下,反应20min,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化三型胶原蛋白rhCOL III溶液中(pH 5.5,0.5wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在重组人血清白蛋白溶液中(pH 5.5,0.05wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化三型胶原蛋白rhCOL III溶液中(pH 5.5,0.5wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),循环处理5次,获得可降解封堵器F;
(7)可降解封堵器F置于茶多酚(表没食子儿茶素没食子酸酯)溶液中(0.3wt%),常温处理20min,即获得终端产品,即具有抗凝促心肌组织修复的可降解封堵器G。
对本实施例所制备的可降解封堵器G与未经处理的可降解封堵器A进行关于抗血小板黏附与聚集能力、引发的炎症应答水平以及对心肌细胞生长的亲和能力的实验,结果同实施例1一样(因附图与实施例1较为接近,故而本实施例省略附图):涂层改性可以有效提升可降解封堵器的抗血小板黏附与聚集能力,可以有效降低可降解封堵器材料引发的炎症应答水平,可以有效促进可降解封堵器材料表面对心肌细胞生长的亲和能力。
实施例4
一种具有抗凝促心肌组织修复功能的可降解封堵器及其制备方法,包含以下步骤:
(1)配置羊血清白蛋白溶液(0.5wt%);
(2)将采用聚对二氧环己酮材料制备的可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加双氧水(0.01wt%),在60℃条件下,反应30min,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化十七型胶原蛋白溶液中(pH 5.5,1wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在羊血清白蛋白溶液中(pH 5.5,0.5wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化十七型胶原蛋白溶液中(pH 5.5,1wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),循环处理3次,获得可降解封堵器F;
(7)可降解封堵器F置于京尼平溶液中(0.2wt%),常温处理30min,即获得终端产品,即具有抗凝促心肌组织修复的可降解封堵器G。
对本实施例所制备的可降解封堵器G与未经处理的可降解封堵器A进行关于抗血小板黏附与聚集能力、引发的炎症应答水平以及对心肌细胞生长的亲和能力的实验,结果同实施例1一样(因附图与实施例1较为接近,故而本实施例省略附图):涂层改性可以有效提升可降解封堵器的抗血小板黏附与聚集能力,可以有效降低可降解封堵器材料引发的炎症应答水平,可以有效促进可降解封堵器材料表面对心肌细胞生长的亲和能力。
实施例5
一种具有抗凝促心肌组织修复功能的可降解封堵器及其制备方法,包含以下步骤:
(1)配置人血清白蛋白溶液(0.05wt%);
(2)将采用聚对二氧环己酮材料制备的可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加三(2-羧乙基)膦(0.2wt%),在50℃条件下,反应30min,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化三型胶原蛋白溶液中(pH 5.5,0.05wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在人血清白蛋白溶液中(pH 5.5,0.05wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化三型胶原蛋白溶液中(pH 5.5,0.05wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),循环处理2次,获得可降解封堵器F;
(7)可降解封堵器F置于戊二醛溶液中(0.05wt%),常温处理20min,即获得终端产品,即具有抗凝促心肌组织修复的可降解封堵器G。
对本实施例所制备的可降解封堵器G与未经处理的可降解封堵器A进行关于抗血小板黏附与聚集能力、引发的炎症应答水平以及对心肌细胞生长的亲和能力的实验,结果同实施例1一样(因附图与实施例1较为接近,故而本实施例省略附图):涂层改性可以有效提升可降解封堵器的抗血小板黏附与聚集能力,可以有效降低可降解封堵器材料引发的炎症应答水平,可以有效促进可降解封堵器材料表面对心肌细胞生长的亲和能力。
实施例6
一种具有抗凝促心肌组织修复功能的可降解封堵器及其制备方法,包含以下步骤:
(1)配置人血清白蛋白溶液(0.05wt%);
(2)将采用聚对二氧环己酮材料制备的可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加三(2-羧乙基)膦(0.2wt%),在50℃条件下,反应30min,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化三型胶原蛋白溶液中(pH 5.5,0.05wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在人血清白蛋白溶液中(pH 5.5,0.05wt%),常温下处理20min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化三型胶原蛋白溶液中(pH 5.5,0.05wt%),常温下处理10min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),循环处理2次,获得可降解封堵器F;
(7)可降解封堵器F置于茶多酚(表没食子儿茶素没食子酸酯)溶液中(0.3wt%),常温处理20min,即获得终端产品,即具有抗凝促心肌组织修复的可降解封堵器G。
对本实施例所制备的可降解封堵器G与未经处理的可降解封堵器A进行关于抗血小板黏附与聚集能力、引发的炎症应答水平以及对心肌细胞生长的亲和能力的实验,结果同实施例1一样(因附图与实施例1较为接近,故而本实施例省略附图):涂层改性可以有效提升可降解封堵器的抗血小板黏附与聚集能力,可以有效降低可降解封堵器材料引发的炎症应答水平,可以有效促进可降解封堵器材料表面对心肌细胞生长的亲和能力。
以上所述实施例仅表达了本申请的具体实施方式,其描述较为具体和详细,但并不能因此而理解为对本申请保护范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本申请技术方案构思的前提下,还可以做出若干变形和改进,这些都属于本申请的保护范围。
Claims (6)
1.一种抗凝促心肌组织修复的可降解封堵器,其特征在于,所述可降解封堵器的表面覆有多层白蛋白以及重组人源化胶原蛋白层,且以添加活化处理液的白蛋白为打底涂层,表面的白蛋白以及重组人源化胶原蛋白层参与交联反应,所述可降解封堵器的材料采用聚乳酸、聚对二甲基羟己酮、聚对二氧环己酮、聚乳酸羟基乙酸共聚物、聚己内酯中的一种或多种;所述重组人源化胶原蛋白为不含有血小板结核性羟脯氨酸(O)且包含正负电荷相对集中的GER、GEK细胞粘附性序列的重组人源化胶原蛋白多肽片段,经基因工程和发酵工程制备的重组人源化胶原蛋白,其蛋白分型包括重组人源化一型到二十八型,分子量范围为5千~100万。
2.如权利要求1所述的抗凝促心肌组织修复的可降解封堵器,其特征在于:所述白蛋白为牛血清白蛋白、人血清白蛋白、羊血清白蛋白以及它们的重组白蛋白中的一种或多种。
3.如权利要求1或2所述的抗凝促心肌组织修复的可降解封堵器的制备方法,其特征在于,包括如下步骤:
(1)配置白蛋白溶液,浓度为0.01 wt%-2 wt%;
(2)将可降解封堵器A放置于步骤(1)的白蛋白溶液中,添加活化处理液,添加比例为0.05 wt%-2 wt%,在50-80℃条件下,反应10 min-6 h,制备经白蛋白涂层打底的可降解封堵器B;
(3)将可降解封堵器B浸没到重组人源化胶原蛋白溶液中,pH 5.5,浓度0.01 wt%-2wt%,常温下处理10-60 min后取出,用去离子水清洗,获得可降解封堵器C;
(4)将可降解封堵器C浸没在白蛋白溶液中pH 5.5,浓度 0.01 wt%-2 wt%,常温下处理10-60 min后取出,用去离子水清洗,获得可降解封堵器D;
(5)将可降解封堵器D浸没到重组人源化胶原蛋白溶液中,pH 5.5,浓度0.01 wt%-2wt%,常温下处理10-60 min后取出,用去离子水清洗,获得可降解封堵器E;
(6)上述步骤(4)和步骤(5),可循环处理1到10次,获得可降解封堵器F;
(7)可降解封堵器F置于交联剂溶液中,交联剂浓度为0.01 wt%-1 wt%,常温处理10min-60 min,即获得具有抗凝促心肌组织修复的可降解封堵器G。
4.如权利要求3所述的抗凝促心肌组织修复的可降解封堵器的制备方法,其特征在于:步骤(2)中,所述活化处理液为还原性谷胱甘肽、过硫酸盐、三(2-羧乙基)膦、双氧水及其他能产生活性自由基的化合物中的一种或多种。
5.如权利要求3所述的抗凝促心肌组织修复的可降解封堵器的制备方法,其特征在于:步骤(7)所述交联剂为戊二醛、京尼平、碳二亚胺盐酸盐类、多酚类化合物中的一种或多种。
6.如权利要求1或2所述的抗凝促心肌组织修复的可降解封堵器在左心耳封堵器、房间隔、室间隔封堵器、卵圆孔未闭封堵器上的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022101864513 | 2022-02-28 | ||
CN202210186451 | 2022-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114632195A CN114632195A (zh) | 2022-06-17 |
CN114632195B true CN114632195B (zh) | 2023-01-06 |
Family
ID=81951474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210458430.2A Active CN114632195B (zh) | 2022-02-28 | 2022-04-27 | 一种抗凝促心肌组织修复的可降解封堵器及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114632195B (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010069306A (ja) * | 2008-09-17 | 2010-04-02 | National Institute Of Advanced Industrial Science & Technology | 組換えヒト血清アルブミンを用いた生体材料 |
US9474834B2 (en) * | 2014-04-11 | 2016-10-25 | Abbott Cardiovascular Systems Inc. | Stent with albumin coating for enhanced thromboresistance |
CN109731137B (zh) * | 2019-03-13 | 2021-05-07 | 陕西师范大学 | 具有生物抗污功能的白蛋白涂层的制备方法及具有生物抗污功能的材料 |
CN109821076B (zh) * | 2019-03-13 | 2021-05-07 | 陕西师范大学 | 一种抗凝抗感染的多功能涂层的制备方法及抗凝抗感染的多功能材料 |
CN111467574B (zh) * | 2020-04-21 | 2021-01-26 | 四川大学 | 基于edc/nhs活化和重组人源胶原蛋白修饰的生物瓣膜材料及其制备方法 |
CN111569160B (zh) * | 2020-05-26 | 2021-05-11 | 四川大学 | 基于重组人源胶原蛋白的多功能支架涂层及其制备方法 |
CN113769177B (zh) * | 2021-08-26 | 2022-05-27 | 四川大学 | 一种可降解封堵器涂层及其制备方法 |
-
2022
- 2022-04-27 CN CN202210458430.2A patent/CN114632195B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114632195A (zh) | 2022-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018196088A1 (zh) | 一种在医用镁合金表面制备壳聚糖/肝素化氧化石墨烯复合多层膜的方法 | |
US6322588B1 (en) | Medical devices with metal/polymer composites | |
JPH1052488A (ja) | バイオ分子でコートされた表面グラフトマトリックスを有する医学装置 | |
CN114748707A (zh) | 一种可降解封堵器抗凝血及快速内皮化涂层及其制备方法 | |
WO2008147867A2 (en) | Cross-linked collagen and uses thereof | |
WO2007108450A1 (ja) | 医療用生分解性マグネシウム材 | |
JPH03254752A (ja) | 人工血管及びその製造方法 | |
WO1996023533A1 (fr) | Materiau a usage medical et son procede de fabrication | |
JP2009153947A (ja) | 神経再生誘導管 | |
WO2009049494A1 (fr) | Stent artificiel et procédé de préparation dudit stent | |
CN104784750A (zh) | 提高变形性生物镁合金植入器件耐蚀性的表面改性方法 | |
AU2006288336A1 (en) | Tissue regeneration substrate | |
CN104028434B (zh) | 一种在钛表面构建层粘连蛋白/肝素/SDF-1α抗凝及诱导内皮化多功能层的方法 | |
CN114632195B (zh) | 一种抗凝促心肌组织修复的可降解封堵器及其制备方法 | |
JP2008099565A (ja) | 心筋培養用のスポンジ状シート | |
WO2021164626A1 (zh) | 一种功能化生物基质材料及其制备方法和应用 | |
CN102094227A (zh) | 在钛种植体表面制备壳聚糖丝素蛋白复合涂层的电化学方法 | |
CN111701077A (zh) | 一种具有抗血栓抗钙化功能的瓣膜及其制备方法和应用 | |
US11724004B2 (en) | Transglutaminase treated products | |
CN115025294B (zh) | 一种可降解封堵器的促内皮化表面改性方法及其制备的改性可降解封堵器 | |
CN114796623B (zh) | 一种促心肌组织修复的全降解心脏封堵器涂层及其制备方法 | |
CN111454480B (zh) | 一种细胞外基质涂层增强高分子瓣膜生物相容性的方法 | |
CN114652366B (zh) | 一种心脏封堵器用可降解复合膜及其制备方法和应用 | |
CN116603118B (zh) | 一种具有ecm重建功能的全降解封堵器及涂层制备方法 | |
WO2018222434A1 (en) | Collagen fibers and articles formed therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231214 Address after: 201612 floor 1 and 5, building 41, No. 258, Xinzhuan Road, Songjiang hi tech park, Shanghai Caohejing Development Zone, Songjiang District, Shanghai Patentee after: SHANGHAI SHAPE MEMORY ALLOY Co.,Ltd. Address before: 610065, No. 24, south section of first ring road, Chengdu, Sichuan, Wuhou District Patentee before: SICHUAN University |